🌸 Estrogen Progesterone Combination Regimen Simulator

Why Progesterone Accompanies Estrogen When the Uterus Is Intact

Placeholder: unopposed estrogen thickens the endometrium unchecked.

• ↑ 8x: Unopposed EE risk (Placeholder relative risk figure)
• Uterus intact: Applies when (Placeholder condition)
• Add progestin: Mitigation (Placeholder mitigation)
• Dose-dependent: Exposure duration (Placeholder note)

Unopposed estrogen risk

Placeholder: chronic estrogen exposure without progestin promotes hyperplasia.

Placeholder: progestin co-therapy is standard of care with a uterus.

How Progesterone Protects the Endometrium

Placeholder: progesterone opposes estrogen-driven glandular growth.

• Antiproliferative: Mechanism (Placeholder mechanism label)
• Endometrium: Target tissue (Placeholder tissue)
• PR-mediated: Receptor (Placeholder receptor note)
• Reduced hyperplasia: Outcome (Placeholder outcome)

Progesterone receptor action

Placeholder: progesterone promotes secretory transformation and shedding.

Placeholder: adequate dose and duration matter for protection.

Cyclic Versus Continuous Combined Regimens

Placeholder: two dosing schedules trade off bleeding for predictability.

• Monthly: Cyclic bleed (Placeholder pattern)
• Irregular→none: Continuous bleed (Placeholder pattern)
• ~12 months: Time to amenorrhea (Placeholder estimate)
• Varies: Patient preference (Placeholder note)

Scheduling tradeoffs

Placeholder: cyclic mimics a natural cycle; continuous avoids scheduled bleeds.

Placeholder: choice depends on patient tolerance for spotting.

Estrogen-Only Therapy After Hysterectomy

Placeholder: without a uterus, progestin adds no protective benefit.

• None: Progestin need (Placeholder condition)
• N/A: Endometrial risk (Placeholder — no endometrium)
• ET alone: Regimen (Placeholder label)
• Lower: Side-effect load (Placeholder comparison)

Simplified therapy

Placeholder: estrogen-only avoids unnecessary progestin exposure.

Placeholder: hysterectomy status simplifies regimen choice.

Choosing a Regimen From Patient Factors

Placeholder: uterus status and bleeding preference set the final regimen.

• Uterus status: Key input 1 (Placeholder factor)
• Regimen type: Key input 2 (Placeholder factor)
• Regimen match: Output (Placeholder result)
• Annual: Review cadence (Placeholder cadence)

Combining the factors

Placeholder: match therapy type to individual risk and preference.

Placeholder: shared decision-making guides final selection.